BRCA1 antibody

Breast cancer 1, early onset (BRCA1) is a well-known tumor suppressor gene that was originally discovered due to its link with early-onset breast and ovarian cancer in women. The BRCA1 protein contains the following domains: RING finger, RAD51-interaction, and BRCT (BRCA1 C-terminus). The N-terminus RING domain enables binding to several proteins - including BARD1 (BRCA1-associated RING domain protein) - allowing the formation of heterodimers. The RING finger is important for tumor suppressor activity. The RAD51-interaction domain is involved in DNA double-stranded break (DSB) repair.

Nucleolin is an abundant, 106 kDa nucleolar phosphoprotein that is a major protein in actively dividing cells. The stability of nucleolin is heavily cell proliferation-dependent, as nucleolin antibody studies have shown that degraded forms are relatively abundant in quiescent non-dividing cells, while nonexist in actively dividing cells.

Mediating DNA damage is a crucial process, and one of the most important cellular guards against cancer. In response to DNA damage, sophisticated cellular machinery is recruited to repair the breaks, and if it fails, the cell is committed to death.

In the United States, breast cancer is one of the most common cancers and the second leading cause of cancer related deaths in women. According to the American Cancer Society's most recent estimates for breast cancer in the United States, there are about 200,000 new cases of invasive breast cancer, 60,000 new cases of carcinoma in situ (CIS),  and approximately 40,000 deaths from breast cancer this year.

BRCA1, also known as breast cancer type 1 susceptibility protein and RING finger protein 53, belongs to a class of genes known as tumor suppressors. BRCA1 regulates cell growth and division, and is also involved in DNA repair.

Our antibody catalog includes an extensive range of Rad51 antibody reagents. Encoded by the RAD51 gene, the Rad51 protein plays a vital role in DNA repair, interacting with several other proteins, including BRCA1 and BRCA2, to effect homologous recombination at double-strand breaks.

Human cancer research is the largest research area in our antibody database, with new oncogenes and cell lines being added all the time.

We at Novus Biologicals have an extensive antibody databasedevoted to the 13 Fanconi anaemia complementation (FANC) genes, which are involved in the recognition and repair of damaged DNA.

Our antibody database at Novus Biologicals provides research tools for the forefront of cancer research. Recently, a mouse study using 53BP1 and BRCA1 antibodies showed that deletion of 53BP1 greatly lessened the incidence of tumor development in mice carrying the mutated BRCA1 gene.

Fanconi anaemia (FA) is an autosomal-recessive disorder, characterized by skeletal abnormalities, progressive bone marrow failure and cellular hypersensitivity to DNA damaging agents such as Mitomycin C. FA also increases the likelihood of cancerous tumors and childhood leukemia.